KR101445458B1 - １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체 - Google Patents
１Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체 Download PDFInfo
- Publication number
- KR101445458B1 KR101445458B1 KR1020127000098A KR20127000098A KR101445458B1 KR 101445458 B1 KR101445458 B1 KR 101445458B1 KR 1020127000098 A KR1020127000098 A KR 1020127000098A KR 20127000098 A KR20127000098 A KR 20127000098A KR 101445458 B1 KR101445458 B1 KR 101445458B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- quinolin
- dihydro
- imidazo
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(c(I=N)c1)c(*)c(nc2*)c1c(*)c2[N+]([O-])=O Chemical compound *c(c(I=N)c1)c(*)c(nc2*)c1c(*)c2[N+]([O-])=O 0.000 description 29
- YRTIPZUNGYBTAI-UHFFFAOYSA-O CC(C(C[NH2+]C)C1=Cc2c(cc(cc3)-c(cn4)ccc4OCC[O](Cc4ccccc4)=C)c3ncc2N(C)C1=O)=N Chemical compound CC(C(C[NH2+]C)C1=Cc2c(cc(cc3)-c(cn4)ccc4OCC[O](Cc4ccccc4)=C)c3ncc2N(C)C1=O)=N YRTIPZUNGYBTAI-UHFFFAOYSA-O 0.000 description 1
- VOMUOHJLYTYKLU-UHFFFAOYSA-O CC(C(N(c1c(cc(cc2)-c(cc3)cnc3-[n]3nccc3)c2ncc1N1C)C1=O)=C=[NH2+])=N Chemical compound CC(C(N(c1c(cc(cc2)-c(cc3)cnc3-[n]3nccc3)c2ncc1N1C)C1=O)=C=[NH2+])=N VOMUOHJLYTYKLU-UHFFFAOYSA-O 0.000 description 1
- LDNRGBSBPGMGPI-UHFFFAOYSA-O CC(C(N(c1c(cc(cc2)-c3ccccc3)c2ncc1N1)C1=O)=C[NH2+]C)NC Chemical compound CC(C(N(c1c(cc(cc2)-c3ccccc3)c2ncc1N1)C1=O)=C[NH2+]C)NC LDNRGBSBPGMGPI-UHFFFAOYSA-O 0.000 description 1
- YWRBLSYOLXMZGA-UHFFFAOYSA-N CC1(C)OB(c2c[n](CCOC3OCCCC3)nc2)OC1(C)C Chemical compound CC1(C)OB(c2c[n](CCOC3OCCCC3)nc2)OC1(C)C YWRBLSYOLXMZGA-UHFFFAOYSA-N 0.000 description 1
- UMNHNYSMUMUXMG-UHFFFAOYSA-N CC1(C)OB(c2ccc(N3CCC3)nc2)OC1(C)C Chemical compound CC1(C)OB(c2ccc(N3CCC3)nc2)OC1(C)C UMNHNYSMUMUXMG-UHFFFAOYSA-N 0.000 description 1
- MDQFPCPLPMLWQE-UHFFFAOYSA-O CCC(CC)CC1=C(C)NCC(c(ccc2ncc3N4C)cc2c3N(C(C(C)=N)=C[NH2+]C)C4=O)=C1 Chemical compound CCC(CC)CC1=C(C)NCC(c(ccc2ncc3N4C)cc2c3N(C(C(C)=N)=C[NH2+]C)C4=O)=C1 MDQFPCPLPMLWQE-UHFFFAOYSA-O 0.000 description 1
- IPRBGSHKJYVKMQ-UHFFFAOYSA-N CCC(CC1)N=C(C)C1N(c(c(cc(cc1)-c2cncc(OC3CCC3)c2)c1nc1)c1N1C)C1=O Chemical compound CCC(CC1)N=C(C)C1N(c(c(cc(cc1)-c2cncc(OC3CCC3)c2)c1nc1)c1N1C)C1=O IPRBGSHKJYVKMQ-UHFFFAOYSA-N 0.000 description 1
- ZIRKWXVVWHTKJA-UHFFFAOYSA-O CCN(C)C(C[NH2+]C=C(C(C)=N)N(c1c(cc(cc2)-c3ccccc3)c2ncc1N1C)C1=O)=O Chemical compound CCN(C)C(C[NH2+]C=C(C(C)=N)N(c1c(cc(cc2)-c3ccccc3)c2ncc1N1C)C1=O)=O ZIRKWXVVWHTKJA-UHFFFAOYSA-O 0.000 description 1
- QZWGMFPVRXMGNO-UHFFFAOYSA-N CCNC(c1cc(S2OC(C)(C)C(C)(C)O2)cnc1NC)=O Chemical compound CCNC(c1cc(S2OC(C)(C)C(C)(C)O2)cnc1NC)=O QZWGMFPVRXMGNO-UHFFFAOYSA-N 0.000 description 1
- IUAYLJIEHYDJLS-UHFFFAOYSA-O CCOc1cncc(-c(ccc2ncc3N4C)cc2c3N(C(C[NH2+]C)C(C)=N)C4=O)c1 Chemical compound CCOc1cncc(-c(ccc2ncc3N4C)cc2c3N(C(C[NH2+]C)C(C)=N)C4=O)c1 IUAYLJIEHYDJLS-UHFFFAOYSA-O 0.000 description 1
- GRFCJZIHPOHZAL-UHFFFAOYSA-O CC[NH2+]C=C(C(C)=N)N(c(c(cc(cc1)-c(cc2OCC)ccc2OCC)c1nc1)c1N1C)C1=O Chemical compound CC[NH2+]C=C(C(C)=N)N(c(c(cc(cc1)-c(cc2OCC)ccc2OCC)c1nc1)c1N1C)C1=O GRFCJZIHPOHZAL-UHFFFAOYSA-O 0.000 description 1
- AHOJCZFQXZGFMZ-UHFFFAOYSA-O C[NH2+]C=C(C(Cl)=N)N(c1c(cc(C2C=NC(OC)=C(COC)C2)cc2)c2ncc1N1C)C1=O Chemical compound C[NH2+]C=C(C(Cl)=N)N(c1c(cc(C2C=NC(OC)=C(COC)C2)cc2)c2ncc1N1C)C1=O AHOJCZFQXZGFMZ-UHFFFAOYSA-O 0.000 description 1
- DOAAPYLUVPPLPI-UHFFFAOYSA-N Cc1n[n](C)c(N(c(c2nc(-c3ccc(C)c(OC)c3)ccc2nc2)c2N2C)C2=O)c1 Chemical compound Cc1n[n](C)c(N(c(c2nc(-c3ccc(C)c(OC)c3)ccc2nc2)c2N2C)C2=O)c1 DOAAPYLUVPPLPI-UHFFFAOYSA-N 0.000 description 1
- PFEQWFLEEJGWPM-UHFFFAOYSA-N Cc1n[n](C)cc1N(C1c2cc(-c3cccc(S(N4CCCC4)=O)c3)ccc2N=CC1N1C)C1=O Chemical compound Cc1n[n](C)cc1N(C1c2cc(-c3cccc(S(N4CCCC4)=O)c3)ccc2N=CC1N1C)C1=O PFEQWFLEEJGWPM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18414109P | 2009-06-04 | 2009-06-04 | |
| US61/184,141 | 2009-06-04 | ||
| PCT/EP2010/057719 WO2010139731A1 (en) | 2009-06-04 | 2010-06-02 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120034710A KR20120034710A (ko) | 2012-04-12 |
| KR101445458B1 true KR101445458B1 (ko) | 2014-10-07 |
Family
ID=42697442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127000098A Expired - Fee Related KR101445458B1 (ko) | 2009-06-04 | 2010-06-02 | １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8476294B2 (enExample) |
| EP (1) | EP2438064A1 (enExample) |
| JP (1) | JP5596137B2 (enExample) |
| KR (1) | KR101445458B1 (enExample) |
| CN (1) | CN102574845B (enExample) |
| AR (1) | AR076949A1 (enExample) |
| AU (1) | AU2010255727B2 (enExample) |
| BR (1) | BRPI1010621A2 (enExample) |
| CA (1) | CA2763821A1 (enExample) |
| CL (1) | CL2011003052A1 (enExample) |
| CO (1) | CO6470887A2 (enExample) |
| CR (1) | CR20110608A (enExample) |
| CU (1) | CU24064B1 (enExample) |
| DO (1) | DOP2011000373A (enExample) |
| EA (1) | EA020715B1 (enExample) |
| EC (1) | ECSP11011500A (enExample) |
| GE (1) | GEP20156267B (enExample) |
| IL (1) | IL216452A0 (enExample) |
| MA (1) | MA33332B1 (enExample) |
| MX (1) | MX2011012943A (enExample) |
| NI (1) | NI201100209A (enExample) |
| NZ (1) | NZ596487A (enExample) |
| PE (1) | PE20120224A1 (enExample) |
| SG (1) | SG176572A1 (enExample) |
| TN (1) | TN2011000626A1 (enExample) |
| TW (1) | TWI464168B (enExample) |
| UA (1) | UA106074C2 (enExample) |
| UY (1) | UY32682A (enExample) |
| WO (1) | WO2010139731A1 (enExample) |
| ZA (1) | ZA201108439B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| KR20140014104A (ko) * | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| JP5820080B2 (ja) * | 2011-11-17 | 2015-11-24 | 山▲東▼▲軒▼竹医▲葯▼科技有限公司 | 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤 |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| BR112015025686B1 (pt) | 2013-04-15 | 2020-10-27 | Fmc Corporation | composto, composições fungicidas e método para o controle das doenças dos vegetais |
| JP6576929B2 (ja) * | 2013-09-11 | 2019-09-18 | メルク パテント ゲーエムベーハー | ヘテロ環化合物 |
| JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
| US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
| CA2931147C (en) * | 2013-11-20 | 2018-05-29 | Beijing Forelandpharma Co. Ltd. | Imidazolone derivatives, pharmceutical compositions and uses thereof |
| NO2714752T3 (enExample) | 2014-05-08 | 2018-04-21 | ||
| JP6195684B2 (ja) | 2014-06-03 | 2017-09-13 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 |
| DK3560924T3 (da) * | 2015-04-02 | 2021-06-28 | Merck Patent Gmbh | Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| US10988472B2 (en) | 2016-10-13 | 2021-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for blocking transmission of malarial parasite |
| LT3554490T (lt) | 2016-12-16 | 2022-04-25 | Idorsia Pharmaceuticals Ltd | Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių |
| CA3050348A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN116574099A (zh) * | 2019-09-23 | 2023-08-11 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| EP4142710B1 (en) | 2020-09-21 | 2024-01-31 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| US20230380203A1 (en) * | 2021-01-26 | 2023-11-23 | Boe Technology Group Co., Ltd. | Quantum dot light-emitting device, display apparatus and manufacturing method |
| JP2024534187A (ja) * | 2021-08-31 | 2024-09-18 | インサイト・コーポレイション | Ｋｒａｓの阻害剤としてのナフチリジン化合物 |
| CN116768928A (zh) * | 2023-06-15 | 2023-09-19 | 上海毕臣生化科技有限公司 | 一种3-叔丁基-5-硼酸酯基吡啶的合成方法 |
| CN117384154A (zh) * | 2023-09-04 | 2024-01-12 | 广州医科大学 | 一种吡咯并喹啉酮化合物、合成方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097641A2 (en) * | 2002-05-21 | 2003-11-27 | Novartis Ag | 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007511575A (ja) | 2003-11-21 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体 |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CN101056877B (zh) | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007056112A2 (en) | 2005-11-04 | 2007-05-18 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods |
| KR20090080530A (ko) | 2006-11-20 | 2009-07-24 | 노파르티스 아게 | 2-메틸-2-[4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조[4,5-ｃ]퀴놀린-1-일)-페닐]-프로피오니트릴의 염 및 결정 형태 |
| RU2478387C2 (ru) * | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
| PL2182948T3 (pl) * | 2007-07-24 | 2013-07-31 | Novartis Ag | Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| EP2474323A3 (en) | 2008-03-26 | 2012-10-10 | Novartis AG | Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| WO2010038165A1 (en) | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en not_active Ceased
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active Expired - Fee Related
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
-
2011
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097641A2 (en) * | 2002-05-21 | 2003-11-27 | Novartis Ag | 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5596137B2 (ja) | １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体 | |
| US20100311714A1 (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | |
| CA2395593C (en) | Azaindoles | |
| CA2451678C (en) | Azaindoles | |
| JP2020509089A (ja) | Ｆｇｆｒ阻害剤およびその使用 | |
| MX2008009557A (es) | Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona. | |
| JP2008519790A (ja) | キナーゼ阻害剤としての１，４−置換ピラゾロピリミジン | |
| AU2013249041A1 (en) | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an HIV infection | |
| JP2012528828A5 (enExample) | ||
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| KR20210083287A (ko) | 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체 | |
| JP4871474B2 (ja) | アザインドール | |
| CA2981365A1 (en) | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170923 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170923 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |